NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical ... its affiliates, or employees. Morningstar is not responsible for any ...

Globus Medical, Inc. (GMED) key stats comparison: compare with other stocks by metrics: valuation, ... Employees 5,300 3,600 4,500 995 14,100 2,000 SA Analysts Covering 1 1 1 1 2-Wall St. Analysts ...

NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical ... complex securities litigation and a team of over 70 ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target ...

On Tuesday, JMP analysts maintained their Market Perform rating on Globus Medical (NYSE:GMED) shares. The firm’s stance comes after Globus Medical reported its first-quarter results for 2025.

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...